Rallybio Corporation Statistics
Share Statistics
Rallybio Corporation has 41.49M shares outstanding. The number of shares has increased by 9.77% in one year.
| Shares Outstanding | 41.49M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.09% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 20.18M |
| Failed to Deliver (FTD) Shares | 3 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 463.36K, so 1.12% of the outstanding shares have been sold short.
| Short Interest | 463.36K |
| Short % of Shares Out | 1.12% |
| Short % of Float | 2.3% |
| Short Ratio (days to cover) | 5.75 |
Valuation Ratios
The PE ratio is -1.3 and the forward PE ratio is -0.89.
| PE Ratio | -1.3 |
| Forward PE | -0.89 |
| PS Ratio | 0 |
| Forward PS | 764.1 |
| PB Ratio | 0.91 |
| P/FCF Ratio | -1.6 |
| PEG Ratio | n/a |
Enterprise Valuation
Rallybio Corporation has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 12.39, with a Debt / Equity ratio of 0.
| Current Ratio | 12.39 |
| Quick Ratio | 12.39 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.37 |
| Cash Flow / Debt | -153.74 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.7% and return on capital (ROIC) is -72.03%.
| Return on Equity (ROE) | -0.7% |
| Return on Assets (ROA) | -0.64% |
| Return on Capital (ROIC) | -72.03% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.73M |
| Employee Count | 43 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -2.04M |
| Effective Tax Rate | 0.03 |
Stock Price Statistics
The stock price has increased by -63.82% in the last 52 weeks. The beta is -1.67, so Rallybio Corporation's price volatility has been lower than the market average.
| Beta | -1.67 |
| 52-Week Price Change | -63.82% |
| 50-Day Moving Average | 1.07 |
| 200-Day Moving Average | 1.38 |
| Relative Strength Index (RSI) | 53.72 |
| Average Volume (20 Days) | 75.04K |
Income Statement
In the last 12 months, Rallybio Corporation had revenue of $0 and earned -$74.56M in profits. Earnings per share was $-1.84.
| Revenue | 0 |
| Gross Profit | -150.00K |
| Operating Income | -78.93M |
| Net Income | -74.56M |
| EBITDA | -72.37M |
| EBIT | - |
| Earnings Per Share (EPS) | -1.84 |
Balance Sheet
The company has $24.49M in cash and $392.00K in debt, giving a net cash position of $24.10M.
| Cash & Cash Equivalents | 24.49M |
| Total Debt | 392.00K |
| Net Cash | 24.10M |
| Retained Earnings | -235.25M |
| Total Assets | 79.01M |
| Working Capital | 70.04M |
Cash Flow
In the last 12 months, operating cash flow was -$60.27M and capital expenditures -$12.00K, giving a free cash flow of -$60.28M.
| Operating Cash Flow | -60.27M |
| Capital Expenditures | -12.00K |
| Free Cash Flow | -60.28M |
| FCF Per Share | -1.49 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
RLYB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -167.27% |
| FCF Yield | -131.48% |
Analyst Forecast
The average price target for RLYB is $8, which is 627.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $8 |
| Price Target Difference | 627.3% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | -3.44 |
| Piotroski F-Score | 4 |